Manage benign prostatic hyperplasia-associated lower urinary tract symptoms using a personalized approach.

<h2 id="Aim">Aim</h2><ul><li>To summarize the available evidence on combination pharmacotherapy for managing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).</li><li>To highlight how treatment can be personalized according to symptom severity, prostate size, comorbidities, patient preferences, and treatment expectations.</li><li>To review the efficacy, tolerability, and clinical positioning of commonly used combination regimens.</li></ul><h2 id="Method">Method</h2><ul><li>Narrative review of currently available evidence on combination pharmacotherapy for BPH-associated LUTS, supported by the 2026 European Association of Urology (EAU) guidelines.</li><li>Evidence included randomized controlled trials and meta-analyses evaluating combinations involving:<ul><li>α1-adrenoceptor antagonists + 5α-reductase inhibitors (5-ARIs)</li><li>α1-adrenoceptor antagonists + PDE5 inhibitors</li><li>β3 agonists + muscarinic receptor antagonists</li></ul></li><li>Clinical considerations included symptom improvement, urinary flow, disease progression, acute urinary retention (AUR), need for surgery, sexual function, and adverse events.</li></ul><h2 id="Results">Results</h2><ul><li>α1-blocker + 5-ARI has the strongest evidence base among combination approaches for BPH-associated LUTS.</li><li>In the 4-year CombAT trial (n=4,844), tamsulosin + dutasteride (Table 1):<ul><li>Significantly prolonged the time to AUR or BPH-related surgery versus tamsulosin alone.</li><li>Provided greater symptom improvement than either tamsulosin or dutasteride alone.</li></ul></li><li>The EAU strongly recommends α1-blocker + 5-ARI in men with moderate-to-severe LUTS and increased risk of disease progression, such as prostate volume &gt;40 mL.</li><li>α1-blocker + PDE5 inhibitor significantly improved IPSS, urinary flow and erectile-function outcomes versus α1-blocker monotherapy in meta-analyses.</li><li>Combination therapy may increase adverse-event burden, emphasizing the importance of balancing efficacy with tolerability and adherence.</li></ul><p><strong>Table 1. Tamsulosin + Dutasteride dual combination therapies for BPH associated lower urinary tract symptoms and supported by the EAU guidelines on non-neurogenic male LUTS</strong></p><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/1791870979706-21c0b2887723-Screenshot_2026-10-13_112554.webp" alt="Tamsulosin + Dutasteride dual combination therapies for BPH" width="1049" height="601"></p><h2 id="Conclusion" data-section="conclusion">Conclusion</h2><ul><li>Management of BPH-associated LUTS should follow a personalized approach, considering symptom severity, prostate size, comorbidities, patient preferences and treatment expectations.</li><li>Combination pharmacotherapy should be considered in men with mixed symptoms or an inadequate response to monotherapy.</li><li>Among available combinations, α1-blocker + 5-ARI is the most extensively studied, with evidence supporting symptom improvement and reduction in disease progression.</li><li>Appropriate patient selection is essential to achieve the optimal balance between symptom control, disease-progression prevention, tolerability and quality of life</li></ul><p><i><strong>Disclaimer:</strong> This scientific information content is facilitated by Mega Lifesciences and is intended for healthcare professionals for their reading and update. Although care has been taken in compiling and checking the information, the facilitator is not responsible, or in any way liable for any errors, omissions or inaccuracies in this content whether arising from negligence or otherwise, however, or for any consequences arising therefrom.</i></p>

1de698d6048b Urology Update   Issue 5   Sept 2026   Final

<ol dir="ltr"><li><a href="#Aim">Aim</a></li><li><a href="#Method">Method</a></li><li><a href="#Results">Results</a></li><li><a href="#Conclusion">Conclusion</a></li></ol>